Related content

A critique of emerging European legislation in the pharmaceutical industry: a clinical trials analysis

By Murray Elizabeth   McAdam Rodney   Burke Moira T  

International Journal of Health Care Quality Assurance, Vol. 17, Iss. 7, 2004-07 ,pp. : 389-393

Emerald Group Publishing Ltd

Access to resources Recommend Favorite

Table 2. Summary of the program implementers’ perceptions toward the program content

By  

International Public Health Journal, Vol. , Iss. , 2018-01 ,pp. : 89-88

Nova Science Publishers, Inc.

Access to resources Recommend Favorite

Health-Related Message Boards/Chat Rooms on the Web: Discussion Content and Implications for Pharmaceutical Sponsorships

By Macias Wendy   Lewis Liza Stavchansky   Smith Tenikka  

Journal of Health Communication, Vol. 10, Iss. 3, 2005-04 ,pp. : 209-223

Taylor & Francis Ltd

Access to resources Recommend Favorite

Financial Risk of the Biotech Industry versus the Pharmaceutical Industry

By Golec Joseph   Vernon John A.  

Applied Health Economics and Health Policy, Vol. 7, Iss. 3, 2009-09 ,pp. : 155-165

Adis International

Access to resources Recommend Favorite

Pharmaceutical Websites and the Communication of Risk Information

By Davis Joel   Cross Emily   Crowley John  

Journal of Health Communication, Vol. 12, Iss. 1, 2007-01 ,pp. : 29-39

Taylor & Francis Ltd

Access to resources Recommend Favorite